Illumina sequencing and array technologies drive advances in life science research, translational and consumer genomics, and molecular diagnostics.

Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated …

Illumina (ILMN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- …

Dec 1, 2025 · Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function.

Jun 26, 2024 · In August 2021, Illumina executed an acquisition of GRAIL, a move indicative of Illumina’s strategic interest in expanding its footprint within the healthcare sector.

3 days ago · Illumina (ILMN) has been grinding higher over the past month, even though the stock is still down over the past year, raising a simple question for investors: is this quiet rebound …

5 days ago · NEW YORK – Illumina has long been content to supply as many sequencing reagents as the pharmaceutical industry could handle, but now the firm is willing to offer a …

We are Illumina We are a global genomics and human health leader innovating the future of precision health. We develop DNA sequencing and array-based life sciences technologies to …

5 days ago · Which shareholders are buying/selling shares of Illumina (NASDAQ:ILMN) stock? View ILMN institutional ownership (13F) transactions at MarketBeat.

5 days ago · Illumina (ILMN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher …